Scilex Holding Company Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SCLX, updated each market day.
SCLX AI Sentiment
AI sees no strong directional signal for Scilex Holding Company Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Scilex Holding Company Common Stock
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Sector
Exchange
Market Cap
$48,809,047
Cap Tier
Employees
34
Headquarters
PALO ALTO, CA
Listed Since
Nov. 11, 2022
Website
SCLX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SCLX Volatility
Scilex Holding Company Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
